Cost-Effectiveness Analysis of Dopamine Agonists in the Treatment of Parkinson's Disease in Japan

Author： Shimbo T.  

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.19, Iss.8, 2001-01, pp. : 875-886

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The safety of dopamine agonists in the treatment of Parkinson's disease

By Bonuccelli Ubaldo   Ceravolo Roberto  

Expert Opinion on Drug Safety, Vol. 7, Iss. 2, 2008-03 ,pp. : 111-127

Informa Healthcare

Access to resources Recommend Favorite

Dopamine agonists cost effective for cotherapy of Parkinson's disease?

By  

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 332, 2001-01 ,pp. : 9-9

Adis International

Access to resources Recommend Favorite

Tolerability and Safety of Ropinirole versus Other Dopamine Agonists and Levodopa in the Treatment of Parkinson's Disease: Meta-Analysis of Randomized Controlled Trials

By Kulisevsky Jaime   Pagonabarraga Javier  

Drug Safety, Vol. 33, Iss. 2, 2010-02 ,pp. : 147-161

Adis International

Access to resources Recommend Favorite

Dopamine agonists in Parkinson’s disease

By Tintner Ron   Jankovic Joseph  

Expert Opinion on Investigational Drugs, Vol. 12, Iss. 11, 2003-11 ,pp. : 1803-1820

Informa Healthcare

Access to resources Recommend Favorite

The Role of Dopamine Agonists in the Treatment of Depression in Patients with Parkinson's Disease: A Systematic Review

By Leentjens Albert F.G.  

Drugs, Vol. 71, Iss. 3, 2011-02 ,pp. : 273-286

Adis International

Access to resources Recommend Favorite